TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01906489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548
Description: Oral dose administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
Study: NCT02400281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib besylate
Study: NCT00238914

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Compliance Enhancement (CE)
Description: a controlled therapy intended to simulate outpatient psychiatric care.
Study: NCT01410812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Receive weekly emails asking participants about their exercise and receive cash.
Study: NCT02239614

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDENV-LAV
Description: 0.5 mL of the post-transfection LAV F17 vaccine
Study: NCT01410812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Suggested Tying Intervention
Description: Participants receive 4 iTunes audio novels for their own iPods to listen to only at the gym

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forced Tying Intervention
Description: Participants receive cash and also 4 iTunes audio novels for a loaned iPod accessible only at the gym to listen to only at the gym.
Study: NCT02733653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jetstream Atherectomy System
Description: A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA
Study: NCT03111953

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y Gastric Bypass Surgery
Description: In Roux-en-Y Gastric Bypass Surgery a small gastric pouch is created and connected to a segment of jejunum. Bowel continuity is restored by reconnecting the Roux limb and the biliopancreatic limb approximately \~75-150 cm distal to the gastrojejunostomy. Therefore, ingested food bypasses most of the stomach, the entire duodenum, and a short segment of the jejunum.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biliopancreatic Diversion Surgery
Description: In Biliopancreatic Diversion Surgery a horizontal gastrectomy is conducted leaving a portion of the stomach, which is connected to the small intestine, \~250 cm from the ileocecal valve and the biliopancreatic limb is connected to the ileum, \~50 cm from the ileocecal valve. Digestive secretions from the biliopancreatic limb mix in the common channel, where ingested food is also delivered by the alimentary limb.
Study: NCT01443507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: endurance exercise of different duration and intensity
Description: Two interventions are compared with aerobic capacity as the main outcome. one group exercise at 70% of maximal heart rate for 90 minutes 3 times per week. group two exercise performe10 minutes warm up at 70% of maximal heart rate 4 x 4 minutes intervals at 90-95% of maximal heart rate with 3 minutes active pause at 70% of maximal heart rate in between, and finally 5 minutes cooling down at 70 % of maximal heart rate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: endurance exercise of different duration and intensity
Description: Two interventions are compared with aerobic capacity as the main outcome. one group exercise at 70% of maximal heart rate for 90 minutes 3 times per week. group two exercise performe10 minutes warm up at 70% of maximal heart rate 4 x 4 minutes intervals at 90-95% of maximal heart rate with 3 minutes active pause at 70% of maximal heart rate in between, and finally 5 minutes cooling down at 70 % of maximal heart rate.
Study: NCT00759525

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycyrrhetic Acid
Description: 130 mg daily for fourteen days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily for fourteen days
Study: NCT02738424

Intervention type: OTHER
Intervention: Calculate the ADC scores
Description: The MRI will be performed on the two groups of patients in the usual care. The intervention will be based on the ADC scores calculation. The scores will be obtained with three types of post-processing softwares : Siemens, PACS Carestream, Osirix.

Intervention type: OTHER
Intervention: Calculate the ADC scores
Description: The MRI will be performed on the two groups of patients in the usual care. The intervention will be based on the ADC scores calculation. The scores will be obtained with three types of post-processing softwares : Siemens, PACS Carestream, Osirix.
Study: NCT01174394

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DCEAS (Hwato®/ Dongbang®)
Description: Upon insertion of acupuncture needles, dense cranial electro-acupuncture stimulation (DCEAS), is directly delivered on a density of cranial acupoints (in general 6-8 pairs) located on the frontal, parietal, and temporal scalp areas.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Body electro-acupuncture (Hwato®/ Dongbang®)
Description: Both study arms received body electroacupuncture on both sides of ipsilateral limb pairs: Hegu (LI4) and Quchi (LI11) , Zusanli (ST36) and Taichong (LR3). Electrical stimulation as DCEAS is applied.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Body electro-acupuncture (Hwato®/ Dongbang®)
Description: Both study arms received body electroacupuncture on both sides of ipsilateral limb pairs: Hegu (LI4) and Quchi (LI11) , Zusanli (ST36) and Taichong (LR3). Electrical stimulation as DCEAS is applied.
Study: NCT02239614

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDENV-LAV
Description: 0.5 mL of the post-transfection LAV F17 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDENV-LAV
Description: 0.5 mL of the post-transfection LAV F17 vaccine
Study: NCT03910673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin disodium
Description: Fosfomycin (a phosphonic acid derivative) formulated as a disodium salt.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin disodium
Description: Fosfomycin (a phosphonic acid derivative) formulated as a disodium salt.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin disodium
Description: Fosfomycin (a phosphonic acid derivative) formulated as a disodium salt.
Study: NCT01842997

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: split-virion, non-adjuvanted H1N1 vaccine of 15 μg
Description: 122 participants (19 at 5-9 weeks pregnant,36 at 10-19 weeks pregnant,13 at 20-29 weeks pregnant,54 at more than 30 weeks pregnant) received split-virion, non-adjuvanted H1N1 vaccine of 15 μg.
Study: NCT02720848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stiffening wire
Description: The stiffening wire will be inserted into the double/single balloon enteroscope.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard technique
Description: The double/single balloon enteroscope will be used without the stiffening wire as per standard technique.
Study: NCT04273191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexanolone
Description: Brexanolone will be initiated and administered per the USPI and the associated REMS.
Study: NCT01181570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Patients receive adalimumab 80 mg followed by 40 mg at week 1 and 40 mg every other week (EOW) thereafter.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive 2 injections of placebo at week 0, one injection at week 1 and one injection every other week (EOW) thereafter.
Study: NCT03632018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEART-PLAY
Description: Participants assigned to the HEART-PLAY intervention will receive standard CR. Additionally, they will receive pedometers, group education, and educational materials introduced by peer Health Coaches for 12 months. Before or after their regularly scheduled CR appointments, they will meet at the clinic as a group twice per week to receive Health Tips and participate in discussions. At 8 weeks in to the 12-week CR, they will begin to discuss with their peer Health Coaches the transition from the formal CR setting into community-based exercise. As part of this transition, peer Health Coaches will slowly introduce group community walks and train participants in the proper use of resistance bands. Health Coaches will have talk with their assigned participants about relapse prevention and sustaining exercise following the termination of formal CR.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Cardiac Rehabilitation
Description: During the 12-week intervention period, the STANDARD intervention participants will receive standard of care by attending the 36 sessions of standard CR as prescribed by his/her physician and administered by the Step Clinic.
Study: NCT00803439

Intervention type: DRUG
Intervention: Clobetasol Propionate 0.05% Foam-Reference Product
Description: Small amount applied and evaluated over the course of two days

Intervention type: DRUG
Intervention: Clobetasol Propionate 0.05% Foam-Reference Product
Description: Small amount applied and evaluated over the course of two days

Intervention type: DRUG
Intervention: Clobetasol Propionate 0.05% Foam-Reference Product
Description: Small amount applied and evaluated over the course of two days

Intervention type: DRUG
Intervention: Clobetasol Propionate 0.05% Foam-Reference Product
Description: Small amount applied and evaluated over the course of two days

Intervention type: DRUG
Intervention: Clobetasol Propionate 0.05% Foam-Test product
Description: Small amount applied and evaluated over the course of two days

Intervention type: DRUG
Intervention: Clobetasol Propionate 0.05% Foam-Test product
Description: Small amount applied and evaluated over the course of two days

Intervention type: DRUG
Intervention: Clobetasol Propionate 0.05% Foam-Test product
Description: Small amount applied and evaluated over the course of two days

Intervention type: DRUG
Intervention: Clobetasol Propionate 0.05% Foam-Test product
Description: Small amount applied and evaluated over the course of two days
Study: NCT03020771

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: KIRIM-KONGO-VAX
Description: Crimean-Congo Hemorrhagic Fever Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: KIRIM-KONGO-VAX
Description: Crimean-Congo Hemorrhagic Fever Vaccine
Study: NCT01174394

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: n-CEA (Strietberger®)
Description: Streitberger's non-invasive acupuncture needles were applied to serve as sham control at the same cranial acupoints and the same stimulation modality, except that the needles only adhere to the skin instead of insertion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoxetine
Description: Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
Study: NCT01146288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide first, then Acetazolamide
Description: Two renal function studies will be performed: one before and after intravenous furosemide and the second before and after intravenous acetazolamide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests. A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide first, then Furosemide
Description: Two renal function studies will be performed: one before and after intravenous acetazolamide and the second before and after intravenous furosemide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests.A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.
Study: NCT03198806

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill aerobic exercise in supine position
Description: The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 60 minutes of recovery at the supine position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill aerobic exercise and water intake in supine position
Description: The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 60 minutes of recovery at the supine position.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill aerobic exercise in orthostatic position
Description: The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 10 minutes of recovery at the orthostatic position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill aerobic exercise and water intake in orthostatic position
Description: The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 10 minutes of recovery at the orthostatic position.
Study: NCT02098811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1064nm Laser
Description: Patient will be treated with 1064nm Laser prior to abdominoplasty

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 940nm Laser
Description: Patient will be treated with 940nm Laser prior to abdominoplasty
Study: NCT01270152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: comparing three different doses of ascorbic acid: 50 mg, 100 mg and 200 mg administered inside the catheter and maintained for up to 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: comparing three different doses of ascorbic acid: 50 mg, 100 mg and 200 mg administered inside the catheter and maintained for up to 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: comparing three different doses of ascorbic acid: 50 mg, 100 mg and 200 mg administered inside the catheter and maintained for up to 60 minutes
Study: NCT02047097

Intervention type: DRUG
Intervention: dimethyl fumarate
Description: Provided under routine clinical care
Study: NCT00757692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Vandetanib at 300 mg in combination with Bicalutamide at 50 mg will be administered orally, daily and continuously
Study: NCT05218018

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Lipid drink
Description: 100 mls of heavy cream
Study: NCT00757692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: Bicalutamide at 50 mg will be administered orally, daily and continuously.
Study: NCT03144869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity monitor and feedback
Description: Children will wear a Runscribe accelerometer for two weeks (children in Arm 2 will also wear a CGM). Runscribe will measure activity levels. Activity data will be downloaded by a researcher, analysed and graphs of daily activity levels prepared. At the child's next routine clinic appointment, child and parent will have 1:1 session with researcher acting as 'physical activity champion'. Session content will be informed by Phase 1, but will involve educational support around PA (including barriers and facilitators to participation) and individualised feedback on PA level). Individualised feedback will involve review of daily PA graphs - addressing times of high and low activity levels. For participants in Arm 2, there will also be review of daily line graphs showing BG trends. As part of standard clinical care, CGM data gets downloaded at routine clinic appointments and is visible on the patient's clinic notes in daily graph form.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity monitor and feedback
Description: Children will wear a Runscribe accelerometer for two weeks (children in Arm 2 will also wear a CGM). Runscribe will measure activity levels. Activity data will be downloaded by a researcher, analysed and graphs of daily activity levels prepared. At the child's next routine clinic appointment, child and parent will have 1:1 session with researcher acting as 'physical activity champion'. Session content will be informed by Phase 1, but will involve educational support around PA (including barriers and facilitators to participation) and individualised feedback on PA level). Individualised feedback will involve review of daily PA graphs - addressing times of high and low activity levels. For participants in Arm 2, there will also be review of daily line graphs showing BG trends. As part of standard clinical care, CGM data gets downloaded at routine clinic appointments and is visible on the patient's clinic notes in daily graph form.
Study: NCT02790021

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphaticovenous anastomosis (LVA)
Description: LVA is a minimally invasive procedure that can be performed under local anesthesia. Indocyanine green (ICG) lymphography is used to visualize the (obstructed) lymphatic vessels. When using the images as a guide, the lymphatic pathways and the sites for incisions for lymphaticovenous anastomoses are marked with a pen. The patient's limb is then prepared for surgery. Under a surgical microscope the lymphatic vessels are identified and viable lymphatic vessels are anastomosed to similarly sized adjacent recipient venules in the subdermal plane.
Study: NCT03120377

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platform
Description: Whole body vibration training will consist of 12 consecutive weeks with two sessions per week on alternate days. Initially, before training with the vibratory platform, stretches lasting 5 to 10 minutes will be performed, with a series of 60 seconds for each of the following muscle groups: pectorals, sternocleidomastoids, scalenes, quadriceps and ischiatibial muscles. Patients will be monitored through vital signs for follow-up.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Platform sham
Description: will receive the treatment without the therapeutic effect of the platform, but with vibrating platform connected with the display lit and a sound device coupled with a noise recording generated by the vibration, but without therapeutic purposes.
Study: NCT03670784

Intervention type: OTHER
Intervention: No intervention
Description: No intervention, epidemiological investigation

Intervention type: OTHER
Intervention: No intervention
Description: No intervention, epidemiological investigation
Study: NCT02515201

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taurolidine
Description: taurolidine in central catheter lumen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: heparin in central venous catheter lumen
Study: NCT03462186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthfinder invitation
Description: Invitation to use healthfinder (healthfinder.gov/myhealthfinder
Study: NCT01778920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC17 imaging contrast agent
Description: This is an imaging agent to locate lung adenocarcinoma cancer cells during surgery
Study: NCT00443781

Intervention type: PROCEDURE
Group type: OTHER
Intervention: functional anesthetic discography
Description: Functional Anesthetic Discography (F.A.D.) involves the placement and anchoring of a small catheter into a disc. After placement, functional testing is performed, in which the subject elicits his/her back pain via functional maneuvers or postures. Local anaesthetic is then delivered into the target disc through the catheter and the effect on functional back pain is noted.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: provocative discography
Description: Provocative discography (PD) has been used as a preoperative diagnostic tool for patients with back pain attributed to degenerative disc disease considering lumbar disc surgery. During PD, a clinically suspected disc is accessed with a needle and injected under pressure with radiopaque contrast dye. The subject rates his/her experience of pain for intensity and whether the pain is exactly the same as (concordant) or different from (not concordant or discordant) typical back pain.
Study: NCT00678548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pleasant guided imagery
Description: CD with pleasant guided imagery

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain diary
Description: Filling out a pain diary
Study: NCT02475616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCO371

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02767739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical, social and cultural activities
Description: This intervention included two 60-min aerobic exercise sessions per week. Each session was supervised by a physical activity specialist and walking and stretching exercises were performed after programmed exercise sessions. PHC nurses were prepared to advise patients about the health benefits of PA and used different strategies to encourage the adherence of participants to the program. In addition, social and cultural support activities were included in this intervention program. These activities were performed once a month and they included: visits to museums and libraries, cultural exhibitions, tourist attractions and dance lessons.